AR021405A1 - Composiciones de beta-lactama - Google Patents

Composiciones de beta-lactama

Info

Publication number
AR021405A1
AR021405A1 ARP990106024A ARP990106024A AR021405A1 AR 021405 A1 AR021405 A1 AR 021405A1 AR P990106024 A ARP990106024 A AR P990106024A AR P990106024 A ARP990106024 A AR P990106024A AR 021405 A1 AR021405 A1 AR 021405A1
Authority
AR
Argentina
Prior art keywords
axetil
cefuroxime
compositions
lactama
beta
Prior art date
Application number
ARP990106024A
Other languages
English (en)
Original Assignee
Biochemie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biochemie Gmbh filed Critical Biochemie Gmbh
Publication of AR021405A1 publication Critical patent/AR021405A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

Cefuroxima-axetil en una forma no gelatinosa al contacto con un líquido acuoso, por ejemplo en la forma de una solucion solida en un polímero, o en laforma de una dispersion solida en un vehículo, por ejemplo util para la produccion de composicionesfarmacéuticas que comprenden cefuroxima-axetil como uningrediente activo, y el uso de cefuroxima-axetil en la fabricacion de una forma de dosificacion oral que no exhibe un efecto de alimento adverso.
ARP990106024A 1998-11-26 1999-11-25 Composiciones de beta-lactama AR021405A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0198998A AT413647B (de) 1998-11-26 1998-11-26 Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten

Publications (1)

Publication Number Publication Date
AR021405A1 true AR021405A1 (es) 2002-07-17

Family

ID=3525440

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106024A AR021405A1 (es) 1998-11-26 1999-11-25 Composiciones de beta-lactama

Country Status (30)

Country Link
US (1) US6727243B1 (es)
EP (1) EP1133298B1 (es)
JP (1) JP2002530338A (es)
KR (1) KR20010080566A (es)
CN (1) CN1330546A (es)
AR (1) AR021405A1 (es)
AT (3) AT413647B (es)
AU (1) AU759517B2 (es)
BR (1) BR9915694A (es)
CA (1) CA2348876A1 (es)
CO (1) CO5190668A1 (es)
CZ (1) CZ20011845A3 (es)
DE (1) DE69935609T2 (es)
ES (1) ES2285866T3 (es)
HU (1) HUP0104412A3 (es)
ID (1) ID28615A (es)
IL (1) IL142762A0 (es)
MY (1) MY129564A (es)
NO (1) NO20012526L (es)
NZ (1) NZ511588A (es)
PE (1) PE20001326A1 (es)
PL (1) PL348744A1 (es)
RU (1) RU2248794C2 (es)
SI (1) SI1133298T1 (es)
SK (1) SK7162001A3 (es)
TR (1) TR200101417T2 (es)
TW (1) TWI229603B (es)
WO (1) WO2000030647A1 (es)
YU (1) YU34601A (es)
ZA (1) ZA200103927B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100342943B1 (ko) * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
EP1414417A4 (en) * 2000-12-01 2004-05-06 Abdul Rehman Khan PHARMACEUTICAL FORMULATION
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US6524617B1 (en) * 2001-07-25 2003-02-25 Isp Investments Inc. Synergistic filler composition
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
HRP20020923A2 (en) * 2001-11-23 2003-10-31 Glaxo Group Ltd Pharmaceutical composition
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
WO2004019901A2 (en) * 2002-08-30 2004-03-11 Orchid Chemicals & Pharmaceuticals Ltd. Sustained release pharmaceutical composition
WO2005002540A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Dry powder pharmaceutical suspension compositions of cefuroxime axetil
KR100552567B1 (ko) * 2003-08-23 2006-02-15 한국유나이티드제약 주식회사 수분 흡수에 안정하고 빠르게 붕해되는 세푸록심 악세틸을포함하는 정제의 조성물 및 제조 방법
EP1877041A2 (en) * 2005-04-29 2008-01-16 Cubist Pharmaceuticals, Inc. Therapeutic compositions
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术（石家庄）有限公司 一种微囊化头孢呋辛酯的药物组合物
EP2579860B1 (en) 2010-06-14 2014-04-23 Ratiopharm GmbH Ivabradine-containing pharmaceutical composition with modified release
EP2882423A1 (en) * 2012-08-07 2015-06-17 Sandoz AG Uncoated tablet comprising granules including a -lactam antibiotic and highly dispersed silicone dioxide
CN105338982B (zh) 2013-04-25 2017-10-10 杏林制药株式会社 固体药用组合物
JP5700740B1 (ja) 2013-04-25 2015-04-15 杏林製薬株式会社 固形医薬組成物
WO2016063542A1 (ja) 2014-10-23 2016-04-28 杏林製薬株式会社 固形医薬組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
GB1572993A (en) * 1976-02-16 1980-08-13 Glaxo Operations Ltd Ester derivatives of cefuroxime
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NZ223619A (en) * 1987-02-27 1990-10-26 Lilly Co Eli Sustained release tablet containing cefaclor, a hydrophilic polymer and an acrylic polymer
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
DE3810343A1 (de) * 1988-03-26 1989-10-05 Basf Ag Verfahren zur herstellung von festen pharmazeutischen retardformen
DE4139963A1 (de) * 1991-12-04 1993-06-09 Basf Ag, 6700 Ludwigshafen, De Redispergierbares dispersionspulver aus n-vinylpyrrolidon-vinylacetat-copolymerisat, dessen herstellung und verwendung
DE19602757A1 (de) * 1996-01-26 1997-07-31 Boehringer Mannheim Gmbh Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
US5663258A (en) * 1996-02-20 1997-09-02 Isp Investments Inc. Strongly swellable, moderately crosslinked copolymers of vinylpyrrolidone and vinyl acetate
DE19631085A1 (de) * 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut
WO1998018610A1 (en) * 1996-10-28 1998-05-07 Lengerich Bernhard H Van Embedding and encapsulation of controlled release particles
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
CA2209868C (en) 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
DE69905452D1 (de) 1998-03-03 2003-03-27 Daewoong Pharmaceutical Co Feuchtigkeitsstabile cefuroxim axetil enthaltende pharmazeutische zusammenstellungen
CA2239331C (en) 1998-05-29 1999-11-30 Bernard Charles Sherman Pharmaceutical tablets comprising cefuroxime axetil
DE19835823A1 (de) 1998-08-10 1999-10-07 Lindopharm Gmbh Pharmazeutische Zusammensetzung, Verfahren zu ihrer Herstellung und ihre Verwendung sowie aus ihr hergestellte wässerige Suspension
KR100342943B1 (ko) 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

Also Published As

Publication number Publication date
MY129564A (en) 2007-04-30
ATE357237T1 (de) 2007-04-15
PL348744A1 (en) 2002-06-03
PE20001326A1 (es) 2000-12-12
NO20012526D0 (no) 2001-05-23
BR9915694A (pt) 2001-08-14
CN1330546A (zh) 2002-01-09
ATA198998A (de) 2005-09-15
DE69935609T2 (de) 2007-12-06
AU759517B2 (en) 2003-04-17
ZA200103927B (en) 2002-05-15
CO5190668A1 (es) 2002-08-29
NO20012526L (no) 2001-05-23
NZ511588A (en) 2003-08-29
HUP0104412A3 (en) 2002-08-28
YU34601A (sh) 2004-09-03
JP2002530338A (ja) 2002-09-17
ES2285866T3 (es) 2007-11-16
ID28615A (id) 2001-06-21
TWI229603B (en) 2005-03-21
HUP0104412A2 (hu) 2002-04-29
KR20010080566A (ko) 2001-08-22
WO2000030647A1 (en) 2000-06-02
TR200101417T2 (tr) 2001-11-21
SK7162001A3 (en) 2001-10-08
EP1133298B1 (en) 2007-03-21
DE69935609D1 (de) 2007-05-03
CA2348876A1 (en) 2000-06-02
EP1133298A1 (en) 2001-09-19
AT413647B (de) 2006-04-15
IL142762A0 (en) 2002-03-10
RU2248794C2 (ru) 2005-03-27
US6727243B1 (en) 2004-04-27
AU1654400A (en) 2000-06-13
CZ20011845A3 (cs) 2001-08-15
AT500135A1 (de) 2005-11-15
SI1133298T1 (sl) 2007-10-31

Similar Documents

Publication Publication Date Title
AR021405A1 (es) Composiciones de beta-lactama
AR020392A1 (es) Formulaciones microencapsuladas.
BR0112094A (pt) Produtos de confeitaria contendo ingredientes ativos
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
BR0112495A (pt) Forma de dosagem, processo para a produção de uma forma de dosagem e uso da forma de dosagem
DE69923695D1 (de) Topisch-dermale antimikrobielle zusammensetzungen
CL2009001844A1 (es) Forma de dosificacion farmaceutica solida que comprende lopinavir y ritonavir formulados en forma de dispersion solida o solucion solida, un polimero soluble en agua y un tensioactivo con valores de hlb de entre 4 y 10, util en el tratamiento de una infeccion por vih (divisional sol. 393-06).
DE60118395D1 (de) Pharmazeutische zusammensetzungen mit verzögerter freisetzung für die parenterale applikation von hydrophilen wirkstoffen
CL2010000816A1 (es) Formulacion adecuada para administracion subcutanea que comprende al menos 100 mg/ml de ctlaig, un azucar, y un portador acuoso farmaceuticamente estable; articulo de fabricacion que comprende al menos un recipiente que contiene la formulacion antes mencionada. (divisional solicitud n° 3597-06)
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
NO20034323L (no) Medisinske aerosolformuleringer
BR0302410A (pt) Composição de resposta deflagrada, composição de barreira de resposta deflagrada, dispositivo para a liberação deflagrada de um ou mais ingredientes ativos a um meio lìquido, e, processo para deflagrar a liberação de um ou mais ingredientes a um meio lìquido
PT1077680E (pt) Metodo de fabrico de uma forma de dosagem de agente activo com bandas de libertacao prolongada
DOP2001000297A (es) Nuevas imidazotriazinonas sustituidas
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
CO5011053A1 (es) Procedimiento para la produccion de una forma de dosificacion solida que contiene carvedilol e hidroclorotiazida y formas farmaceuticas obtenidas por dicho procedimiento
ATE316782T1 (de) Neue orale formulierungen für 5-ht4 agonisten oder antagonisten
BR0013012A (pt) Composição contendo substância ativa, sua produção e seu uso
AR025330A1 (es) Combinacion de sustancias activas con clonidina
AR020391A1 (es) Formulaciones microencapsuladas, un procedimiento para su obtencion y empleo de dichas formulaciones.
DK1729732T3 (da) Anioniske hydrogelmatricer med pH-afhængig frigivelse som lægemiddelbærere
AR064104A1 (es) Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas
ECSP066649A (es) Preparado efervescente de una sustancia básica farmacéuticamente activa
BR0314787A (pt) Forma de dosagem de liberação modificada

Legal Events

Date Code Title Description
FA Abandonment or withdrawal